Dr Maria Caffarel
Dr Maria Caffarel is pleased to consider applications from prospective PhD students.
I joined Prof Coleman's laboratory (Department of Pathology, University of Cambridge) last February 2012 to tackle a challenging project based on the study of OSMR as a new therapeutic target for the treatment of cervical SCC. Oncostatin M receptor (OSMR) is commonly over-expressed in cervical cancer and produces a significantly worse clinical outcome. When bound by its principal ligand oncostatin M, OSMR increases the migration and invasiveness of cervical carcinoma cells and induces pro-angiogenic responses. The current project aims to investigate how these changes are achieved, by identifying and characterising the downstream signalling pathways and mediators.
? M. M. Caffarel et al. Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma. J Path 231, 168-79 (2013) ? M. M. Caffarel et al. Cannabinoids: a new hope for breast cancer therapy? Cancer Treatment Reviews 38, 911-918 (2012) ? M. M. Caffarel* et al. Constitutive activation of JAK2in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis. Cell Death & Differentiation 19, 511-522 (2012) (*Corresponding author) ? M. M. Caffarel et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular Cancer 9, 196 (2010) ? M. M. Caffarel et al. Involvement of JunD in the antiproliferative effect of ?9-tetrahydrocannabinol on human breast cancer cells. Oncogene 27, 5033- 5044 (2008). ? M. M. Caffarel et al. D9-Tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 66, 6615- 6621 (2006).